The Motley Fool on MSN9d
Down 93%, Is It Finally Time to Buy Moderna?
This is a low valuation for a drugmaker with two commercial-stage vaccines that you can expect to produce roughly $2 billion ...
Hosted on MSN29d
Moderna’s 2024 Struggles: Navigating Commercial Challenges and Market Competition in the Vaccine Industry
Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your search ...
Rappler5d
Gov’t targets FDA approval for commercial use of ASF vaccines by April
Active cases of African swine fever have dwindled, down to 39 barangays in seven regions as of March 14 from 66 barangays ...